Makena™ Price Reduction Is Inadequate

Main Category: Pregnancy / Obstetrics
Also Included In: Pharma Industry / Biotech Industry;  Regulatory Affairs / Drug Approvals
Article Date: 04 Apr 2011 - 0:00 PDT

Current ratings for:
'Makena™ Price Reduction Is Inadequate'

Patient / Public:not yet rated

Healthcare Prof:not yet rated

Article opinions: 2 posts

Today K-V Pharmaceutical Company announced that it is reducing the cost of its drug Makena™ from $1,500 per dose to $690 per dose, clearly acknowledging the negative impact of their original pricing strategy. Although this may seem like a relatively significant price reduction, unfortunately it remains a woefully inadequate response. This 'lower' price still remains prohibitively high for a safe and effective treatment that is currently available at a much lower price in the form of compounded 17 hydroxyprogesterone caproate (17P).

The American College of Obstetricians and Gynecologists (The College) applauds the US Food and Drug Administration's (FDA) statement that it will not prevent compounding pharmacies from continuing to produce valid prescriptions for 17P, a medication that has been safely used for years to help prevent preterm labor in certain high-risk pregnant women. Although there are clear benefits to having an FDA-approved version of 17P, there is no evidence that Makena™ is more effective or safer than the currently used compounded version. In fact, the evidence used to obtain FDA approval for Makena™ relied primarily on data obtained using the compounded product.

The College, along with the Society for Maternal-Fetal Medicine, American Academy of Pediatrics, American College of Osteopathic Obstetricians & Gynecologists, National Medical Association, American Academy of Family Physicians, American College of Nurse-Midwives, and the Association of Women's Health and Obstetric and Neonatal Nurses, will continue to collaborate to ensure that this medication is accessible and affordable to every pregnant woman who needs it. The US health care system simply cannot be expected to absorb the cost of Makena™ at its current prohibitive price without significant negative repercussions.

Source:
American College of Obstetricians and Gynecologists

View drug information on Makena.


Article adapted by Medical News Today from original press release.
Visit our pregnancy / obstetrics section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
American College of Obstetricians and Gynecologist. "Makena™ Price Reduction Is Inadequate." Medical News Today. MediLexicon, Intl., 4 Apr. 2011. Web.
26 May. 2012. <http://www.medicalnewstoday.com/releases/221109.php>

APA
American College of Obstetricians and Gynecologist. (2011, April 4). "Makena™ Price Reduction Is Inadequate." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/221109.php.

Please note: If no author information is provided, the source is cited instead.



Visitor Opinions (latest shown first)

Dr Mr OBG

posted by John on 7 Apr 2011 at 5:06 pm

And you are ok charging egregious prices for your services and driving home in a BMW? This is yet another knee jerk response from an uninformed MD with zero business sense.

| post followup | alert a moderator |


KV - Makena - LET THEM COMPETE!

posted by Timothy on 4 Apr 2011 at 3:37 pm

I am an OBG doctor. I plan to continue to use the tried-and-true fairly-priced compounded medication. If KV Pharnmaceuticals can make it cheaper in their factory than the pharmacists doing it "by hand" as it were, then they ought to be able corner the market by charging LESS. THAT'S how capitalism is supposed to work, not by making a more expensive product and suing all of your competitors out of business as KV Pharmaceuticals would like to do. THAT's how everything else works - look at cellphones, which are better and *cheaper* tnan the first portable phones that came out decades ago. KV's Makena simply does not contribute anything positive for its enormous cost and, indeed, prices too many patients out of the market altogether.

| post followup | alert a moderator |


Add Your Opinion On This Article

'Makena™ Price Reduction Is Inadequate'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Pregnancy / Obstetrics

Top Tips To Minimize Morning Sickness

Morning sickness affects over half of all pregnant mothers. Our article contains a list of ideas you can put in to practice to minimize unpleasant morning sickness symptoms. Read more...

Most Popular Articles



Follow Our Pregnancy News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pregnancy / Obstetrics Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »